Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chief Executive Officer, is scheduled to present to the investment community at the Bank of America 2006 Specialty Pharmaceuticals Conference, "New Products, New Paradigms."

The conference will be held at the Southampton Inn, in Southampton, NY on August 9-11, 2006. Dr. Cauwenbergh is scheduled to present on Friday, August 11th, 8:45 am Eastern Daylight Time.

The presentation will be available live via a webcast that can be accessed through Barrier Therapeutics' corporate website at: www.barriertherapeutics.com.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, psoriasis, acne, and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. For more information, please visit the company's web site at http://www.barriertherapeutics.com